<DOC>
	<DOCNO>NCT01254526</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib dose-escalation study ass safety , tolerability , pharmacokinetics GDC-0980 administer taxane-based chemotherapy regimen utilized patient locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Study Safety Pharmacology GDC-0980 Combination With Paclitaxel With Without Bevacizumab Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Locally recurrent metastatic breast cancer , amenable resection curative intent For Arm C : Overexpression HER2 Eastern Cooperative Oncology Group Performance Status 0 1 Adequate hematologic organ function Evaluable measurable disease per RECIST ( Response Evaluable Criteria Solid Tumors ) Female patient childbearing potential must use acceptable method contraception prevent pregnancy continue use duration study Prior anticancer therapy two regimen systemic cytotoxic chemotherapy advance metastatic breast cancer Prior anticancer therapy ( e.g. , chemotherapy , biologic therapy , hormonal therapy ) within specify timeframe first dose study treatment History Type 1 Type 2 diabetes require regular medication History clinically significant cardiac pulmonary dysfunction History malabsorption syndrome condition would interfere enteral absorption Any condition require fulldose anticoagulant Leptomeningeal disease manifestation cancer Active infection require IV antibiotic Active autoimmune disease control nonsteroidal antiinflammatory drug , inhale steroid , equivalent &lt; = 10 mg/day prednisone Known clinically significant history liver disease , include active viral , alcoholic , hepatitis , cirrhosis Known HIV infection Known untreated active CNS metastasis Pregnancy , lactation , breastfeed Major surgical procedure , open biopsy , significant traumatic injury within within specified timeframe first dose study treatment For Arm B : Uncontrolled hypertension , complication hypertension , myocardial infarction , unstable angina , vascular disease stroke within specify timeframe first dose study treatment Evidence bleeding diathesis significant coagulopathy include hemoptysis within specify timeframe first dose study treatment History abdominal condition ( e.g. , fistula , perforation , obstruction ) would preclude use bevacizumab Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>